Active Ingredient History

NOW
  • Now
Ocriplasmin is a recombinant protease with activity against fibronectin and laminin, components of the vitreoretinal interface. It is used for treatment of symptomatic vitreomacular adhesion, for which it received FDA approval on 17 October 2012. It works by dissolving the proteins that link the vitreous to the macula, resulting in posterior detachment of the vitreous from the retina.   Wikipedia

More Chemistry

Drug Pricing (per unit)

Australia

$3143.1747
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

jetrea | microplasmin | microplasmin (synthetic human) | ocriplasmin | ocriplasmine | ocriplasmin (genetical recombination) | recombinant human microplasmin

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue